IGF-1 injections alone do not alter the immune phenotype at day 30. by Jordan A. Gunning (18143970)

Prb1 overexpression decreased APCs in ESCRT-mutant cells after nitrogen starvation. by Zulin Wu (4451572)

“…Either Prb1 or Snf7 in <i>snf7Δ</i> cells facilitated GFP-Atg8 degradation and prApe1 maturation (bottom), but only Snf7 (not Prb1) facilitated phagophore closure in <i>snf7Δ</i> cells. The red arrows point to these key results. <b>F.</b> The blots shown in panel E were quantified as described in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1010431#pgen.1010431.g006" target="_blank">Fig 6A and 6B</a>. …”

IGF-1 injections significantly attenuate the increase in macrophages and neutrophils observed at day 30 following IR. by Jordan A. Gunning (18143970)

All-cause gastroenteritis hospitalisations of children decreased after the introduction of rotavirus vaccine in Stockholm by Selma Olsson-Åkefeldt (11500789)

Single color controls for CD3, CD4, CD8, and CD49b antibodies. by Jordan A. Gunning (18143970)

Single color controls for F4/80, Ly-6G, CD11b, and CD45. by Jordan A. Gunning (18143970)

Flow cytometry plots and gating strategy for lymphocytes in IR damaged parotid glands from mice treated with IGF-1. by Jordan A. Gunning (18143970)

Flow cytometry plots and gating strategy for phagocytic immune cells from IR damaged parotid glands. by Jordan A. Gunning (18143970)

Flow cytometry plots and gating strategy for lymphocytes in IR damaged parotid glands. by Jordan A. Gunning (18143970)

Flow cytometry plots and gating strategy for phagocytic immune cells from IR damaged parotid glands in mice treated with IGF-1. by Jordan A. Gunning (18143970)

Image4_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Image2_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Image6_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Image1_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Image3_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Image7_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

Table1_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.xlsx by Mohammad Arif Rahman (8267352)

“…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”

<b>Glucagon Clearance is Decreased in Chronic Kidney Disease, but Preserved in Liver Cirrhosis</b> by Magnus F. G. Grøndahl (19160825)

Decreased risk of Parkinson’s disease in diabetic patients with thiazolidinediones therapy: An exploratory meta-analysis by Yueli Zhu (7526219)

The Transition from a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk by Heba M Ismail (9568748)

“…Conclusions</p> <p>A transition from an increase to a decrease in AUC C-peptide approximately 1.5 years pre-diagnosis was validated in two independent cohorts. …”